Advanced search
Publication Cover
Current Medical Research and Opinion Volume 38, 2022 - Issue 5
Submit an article Journal homepage
2,298
Views
5
CrossRef citations to date
0
Altmetric
Transformation of Mental Health & Brain Disorders Management

Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes

Shonda A. FosterEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USACorrespondence[email protected]
,
Margaret HoytEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
Wenyu YeEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
Oksana MasonEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
&
Janet H. FordEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
Pages 653-660 | Received 17 Aug 2021, Accepted 03 Nov 2021, Published online: 02 Dec 2021

References

  • Headache Classification Committee of the International Headache S. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.
  • Migraine Research Foundation. Migraine facts. [cited August 23, 2020]. Available at: https://migraineresearchfoundation.org/about-migraine/migraine-facts/.
  • Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456–1470.
  • GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17:954–976.
  • Silberstein SD, Lee L, Gandhi K, et al. Health care resource utilization and migraine disability along the migraine continuum among patients treated for migraine. Headache. 2018;58(10):1579–1592.
  • Ford JH, Ye W, Nichols RM, et al. Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey. J Med Econ. 2019;22(9):849–858.
  • Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–349.
  • Raval AD, Shah A. National trends in direct health care expenditures among US adults with migraine: 2004 to 2013. J Pain. 2017;18(1):96–107.
  • Gilligan AM, Foster SA, Sainski-Nguyen A, et al. Direct and indirect costs among United States commercially insured employees with migraine. J Occup Environ Med. 2018;60(12):1120–1127.
  • Bonafede M, Sapra S, Shah N, et al. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. 2018;58(5):700–714.
  • Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22–33.
  • Estemalik E, Tepper S. Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat. 2013;9:709–720.
  • Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478–488.
  • American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18.
  • Huang IH, Wu PC, Lin EY, et al. Effects of anti-calcitonin gene-related peptide for migraines: a systematic review with meta-analysis of randomized clinical trials. Int J Mol Sci. 2019;20(14):3527.
  • Ford JH, Schroeder K, Nyhuis AW, et al. Cycling through migraine preventive treatments: implications for all-cause total direct costs and disease-specific costs. JMCP. 2019;25(1):46–59.
  • IBM Watson Health. IBM MarketScan research databases for health services research–white paper. Somers (NY): IBM; 2018.
  • Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician. 2019;99(1):17–24.
  • Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
  • Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821–1828.
  • Silberstein SD, Olesen J, Bousser MG, et al. The international classification of headache disorders, 2nd edition (ICHD-II)-revision of criteria for 8.2 medication-overuse headache. Cephalalgia. 2005;25(6):460–465.
  • Crump RK, Hotz VJ, Imbens GW, et al. Dealing with limited overlap in estimation of average treatment effects. Biometrika. 2009;96(1):187–199.
  • Yang S, Imbens GW, Cui Z, et al. Propensity score matching and subclassification in observational studies with multi-level treatments. Biometrics. 2016;72(4):1055–1065.
  • Faries DE, Zhang X, Kadziola Z, et al. Real world health care data analysis: Causal methods and implementation using SAS®. Cary (NC): SAS Institute Inc.; 2020.
  • Bonafede M, Cai Q, Cappell K, et al. Factors associated with direct health care costs among patients with migraine. JMCP. 2017;23(11):1169–1176.
  • Affaitati G, Martelletti P, Lopopolo M, et al. Use of nonsteroidal anti-Inflammatory drugs for symptomatic treatment of episodic headache. Pain Pract. 2017;17(3):392–401.
  • Xu H, Han W, Wang J, et al. Network Meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain. 2016;17(1):113.
  • Linde M, Steiner TJ, Chisholm D. Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries. J Headache Pain. 2015;16:15.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.